FDA data Registry peer set 3 peers FDA shortage listed

Alternatives to methotrexate

FDA shortage status is active for methotrexate; 3 same-class SPL records are listed below for registry comparison only.

Brand: Trexall, Otrexup

Disease-Modifying Antirheumatic Drug (DMARD) Prescription 3 alternatives found

methotrexate class peers while FDA lists an active shortage

methotrexate (Trexall, Otrexup) is on an FDA shortage listing while 3 other Disease-Modifying Antirheumatic Drug (DMARD) SPL records remain in this registry peer set (class inventory 4). Labeled indication field for methotrexate: Methotrexate can treat acute lymphoblastic leukemia, a type of cancer, in adults and children.

Top FAERS reaction fields for methotrexate total 263,516 reports across 10 reactions, set beside hydroxychloroquine, leflunomide, sulfasalazine. Counts are exposure-weighted submissions, not per-patient risk.

About methotrexate

Methotrexate is a drug that can treat certain cancers, rheumatoid arthritis, psoriasis, and other conditions. It works by slowing the growth of cells in the body.

Used for: Methotrexate can treat acute lymphoblastic leukemia, a type of cancer, in adults and children. It also treats mycosis fungoides, a skin lymphoma, in adults. Additionally, it treats relapsed or refractory non-Hodgkin lymphoma in adults. For non-cancer conditions, it treats rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis (pJIA) in children, and severe psoriasis in adults.

3 Disease-Modifying Antirheumatic Drug (DMARD) peers (wide set)

Compare methotrexate vs hydroxychloroquine side-by-side →

methotrexate vs hydroxychloroquine & leflunomide · FAERS reaction fields

FAERS top-reaction field "Arthralgia" shows the widest count spread between methotrexate and hydroxychloroquine, leflunomide, sulfasalazine in this extract (19,342-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect methotrexate hydroxychloroquineleflunomidesulfasalazine
Rheumatoid Arthritis 38,053 12,921 24,923 19,190
Arthralgia 36,283 9,276 16,941 13,161
Pain 35,413 10,409 20,055 15,658
Fatigue 29,061 8,853 15,384 13,017
Nausea 24,009 6,584 10,126 8,384
Joint Swelling 22,294 8,528 15,567 12,481
Headache 20,815 5,900 - -
Rash 19,771 7,370 13,321 10,678

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

methotrexate shortage vs Disease-Modifying Antirheumatic Drug (DMARD) peer index

Shortage status

FDA shortage listing is active for methotrexate (status: Current). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for methotrexate while peers remain indexed?
Yes - methotrexate matched an active FDA shortage listing (Current) while 3 other Disease-Modifying Antirheumatic Drug (DMARD) SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full methotrexate profile →

Field note for methotrexate: see also the generic vs brand label guide when reading Trexall SPL strings.